Compare COCP & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCP | SCNX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 16.2M |
| IPO Year | 2011 | 2019 |
| Metric | COCP | SCNX |
|---|---|---|
| Price | $1.01 | $3.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 33.0K | ★ 49.6K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,712,091.00 | $3,831,778.00 |
| Revenue This Year | N/A | $743.36 |
| Revenue Next Year | N/A | $325.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $0.76 | $2.64 |
| 52 Week High | $2.03 | $106.25 |
| Indicator | COCP | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 43.22 | 47.07 |
| Support Level | $0.98 | $2.64 |
| Resistance Level | $1.10 | $10.60 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 42.57 | 49.61 |
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.